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Abstract 
 The growing prevalence of antibiotic-resistant bacteria is a global health crisis that 
threatens the effectiveness of antibiotics in medical treatment. Increases in the number of 
antibiotic-resistant bacteria and a drop in the pharmaceutical development of novel 
antibiotics have combined to form a situation that is rapidly increasing the likelihood of a 
post-antibiotic era. The development of antibiotics with novel enzymatic targets is critical to 
stall this growing crisis. In silico methods of molecular modeling and drug design were 
utilized in the development of novel tryptamine analogs as potential antibiotics through their 
inhibition of the bacterial enzyme tryptophan synthase. Following the creation of novel 
tryptamine analogs, the molecules were analyzed in silico to determine their binding affinity 
to human MAOB and the E. coli α-subunit, E. coli β2-dimer and the M. tuberculosis β2-dimer 
of tryptophan synthase. Ten tryptamine analogs displayed significant increases in tryptophan 
synthase binding affinity and show promise as potential antibiotics and antibiotic adjuvants. 
Further in silico modeling determined that the binding sites of the tryptamine analogs were 
similar to wild-type tryptamine in the E. coli β2-dimer, the M. tuberculosis β2-dimer and 
human MAOB, while the analogs’ binding sites to the E. coli α-subunit differed. Although no 
tryptamine analogs increased tryptophan synthase binding affinity while decreasing human 
MAOB binding affinity, related increases in MAOB binding affinity warrants further 
research into the analogs’ potentials as MAO inhibitors. Given the increases in tryptophan 
synthase binding affinity and similar β2-dimer binding sites, a provisional patent was filed on 
the ten identified tryptamine analogs. Moving forward, we recommend the synthesis of the 
ten identified tryptamine analogs. Following synthesis, further research should be conducted 
to determine the in vitro and in vivo antibiotic properties of the ten tryptamine analogs.    
 
	
4 
Introduction 
The Arms Race – Bacterial Evolution of Antibiotic Resistance  
The pseudo-competition between human development of new antibiotics and the 
subsequent evolution of different antibiotic resistant bacterial strains is akin to an arms race. 
As humans develop a novel antibiotic to combat antibiotic-resistant strains of bacteria, the 
competition induced by this new antibiotic and subsequent bacterial evolution results in 
strains of bacteria that are resistant to the new antibiotic. Those antibiotics with the adaptive 
traits to counteract the mechanisms of the antibiotic outcompete the non-resistant bacteria 
and subsequently produce more antibiotic-resistant bacteria.  
Bacteria can attain antibiotic resistance through two general methods. First, the 
bacteria may acquire a spontaneous genetic mutation through the reproduction process that 
yields resistance to the antibiotic in question. Although such a random mutation is 
exceedingly rare, the rapid speed of reproduction and massive number of bacterial organisms 
allows for such a resistance-causing mutation to occasionally occur. Second, a bacteria 
organism may acquire antibiotic resistance from other bacteria through three methods of 
horizontal gene transfer. During the process of conjugation, the bacteria come into direct 
contact with another and transfer genetic material directly between the two bacterial 
organisms. Bacteria can also perform transformation where they uptake exogenous DNA 
fragments from their surrounding medium. Finally, in the process of transduction a 
bacteriophage virus acts as an intermediate for the transfer of genetic material. The 
bacteriophage uptakes bacterial chromosomal DNA into the head of the virus and this genetic 
material is subsequently transferred to other bacteria the virus infects. All three 
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aforementioned methods of horizontal gene transfer allow for the transfer of antibiotic-
resistance mechanisms from one bacteria to another if the shared genetic material contains a 
gene that encodes for antibiotic resistance.  
Once a bacterial strain acquires antibiotic resistance these bacteria maintain a 
selective advantage over their non-resistant counterparts in the presence of the antibiotic in 
question. When this antibiotic is introduced the non-resistant bacteria are killed off with 
relative ease and the bacteria that remain are those with the antibiotic-resistant gene. Even if 
only one bacterium has acquired antibiotic-resistance, that bacterium is able to rapidly 
reproduce and create entire colonies of bacteria with the same antibiotic-resistant gene after 
the competition from the non-resistant counterparts is eliminated. A recent study reported 
that in 2012 approximately 70% of bacteria that cause human infections were resistant to at 
least one of the drugs that are commonly used to fight them (Bax and Griffin, 2012). 
To eliminate the bacterial colonies that developed resistance to one antibiotic, a 
second antibiotic must be introduced. While this may not present a serious issue if the 
bacterial colony is only resistant to a single antibiotic, it is possible, and increasingly more 
prevalent, for bacteria to be resistant to multiple antibiotics. Multiple-drug resistance (MDR) 
may occur both within a single family of antibiotics and across multiple antimicrobial 
families. Cross-resistance occurs when a bacterial strain is resistant to multiple antibiotics in 
the same family and is usually the result of a single resistance mechanism that inhibits the 
function of multiple alike antibiotics. Bacterial MDR across multiple antibiotic families 
usually occurs as the result of a combination of different independent mechanisms of 
resistance coded for by individual genes. Although these independent mechanisms of 
resistance are coded for by different genes, several of these genes are oftentimes present on a 
 
	
6 
single plasmid that then may be transferred to bacteria through a single act of horizontal gene 
transfer. When a bacterium receives or takes up this plasmid these multiple individual 
mechanisms of resistance are then able to coexist within the bacteria organism, resulting in 
MDR bacterial strains that present resistance across multiple antibiotic families (Brown, 
2010). The most common example of MDR bacterial strains from multiple individual 
resistance-mechanisms is methicillin-resistant S. aureus (MRSA), a bacterial strain that is 
resistant to almost all known antibiotic agents as the result of multiple different mechanisms 
(Nue, 1992).  
Overall, the bacterial development of antibiotic resistance to the antibiotic agents that 
humans discover and develop is inevitable. Gene D. Wright summarizes this inevitability 
when he explains: 
Bacteria are ancient organisms that have adapted to virtually all environmental 
challenges on the planet. They live in environments dominated by small 
molecules and have evolved both specific and nonspecific mechanisms to 
evade or detoxify noxious compounds including antibiotics…There are no 
irresistible antibiotics. (Wright, 2012: 25) 
 
Regardless of the antibiotic, bacterial strains will eventually develop mechanisms that infer 
resistance to the drug molecule. Bacteria have found ways to survive for millions of years 
and they will undoubtedly continue to survive for millions of years more. Earlier research 
noted that a recent database lists more than 20,000 potential resistance genes of 
approximately 400 types found in available bacterial genome sequences (Davies and Davies, 
2010). Therefore, to combat this continual development of antibiotic resistance humans need 
to continually develop novel antibiotics to which bacteria have yet to develop a resistance.  
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Antibiotic Drug Discovery – From Penicillin to the “Golden Age”  
 In 1928 Dr. Alexander Fleming discovered the first antibiotic from the mold 
Penicillium notatum and mass production of penicillin began in the 1940’s. In 1941 all 
strains of Staphylococus aureus were susceptible to penicillin but by 1944 particular strains 
of S.aureus were able to destroy penicillin (Manfredi, 2009; Neu, 1992). Less than fifty years 
later researchers observed that over 95% of S. aureus strains were resistant to penicillin and 
other similar antibiotics (Nue, 1992). While the development of penicillin resistance was the 
first such example of a bacteria developing antibiotic resistance, it was not unexpected. In his 
1945 Nobel Prize Speech Dr. Fleming noted, “It is not difficult to make microbes resistant to 
penicillin in the laboratory by exposing them to concentrations not sufficient to kill them, and 
the same thing has occasionally happened in the body” (Fleming, 1945: 93). Dr. Fleming 
predicted that, although his discovery was one of the most significant of the 21st century, its 
clinical usefulness would begin to decline as bacteria developed resistance to the drug 
through evolutionary pressures.  
After the widespread success of penicillin Dr. Selman Waksman and his cohorts 
began screening soil microbes for potential new antibiotic agents. In 1943 Waksman and his 
graduate assistant Albert Schatz discovered Streptomycin, which successfully killed many 
gram-negative bacteria, most importantly Mycobacterium tuberculosis, the bacteria 
responsible for tuberculosis infections (Gottfried, 2005; White, 2011). Unfortunately, the 
usefulness of Streptomycin was limited by its toxic side effects, most notably ototoxicity 
(White, 2011). However, the work of Dr. Waksman’s lab in identifying soil microbes as 
potential sources of antibiotic agents coupled with the widespread and continued success of 
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penicillin led to what is known as the “golden age of antibiotic discovery” (White, 2011; 
Davies, 2006).  
The widespread commercial success of penicillin, and to a lesser degree 
streptomycin, soon led to a significant investment in antibiotic research from the 
pharmaceutical industry. Every major pharmaceutical company instituted major screening 
programs in an effort to discover their own antibiotics. The vast majority of current antibiotic 
classes were discovered during this “golden era” period spanning from the late 1940’s to 
1960’s (White, 2011; Silver, 2007). By 1952, antibiotics existed to treat infections from both 
gram-positive and gram-negative bacteria (Gottfried, 2005). In only a ten-year period 
spanning from 1950-1960 approximately half of the antibiotics commonly used today were 
discovered (Davies, 2006). The impact of this period of immense antibiotic discovery simply 
cannot be understated. The development of antibiotics over this golden era is credited with 
playing a central role in the transition of worldwide medicine from an “age of pestilence” to 
the modern “age of degenerative [chronic] diseases” (Gottfried, 2005: 10). In 1936, before 
the discovery of penicillin and other antibiotics, approximately 280,000 Americans died of 
bacterial infections. Less than two decades later in 1952 this number dropped to 95,000 
(Gottfried, 2005). Using population estimates at the time that drop correlates to a decrease in 
the bacterial infection death rate from 216/100,000 in 1936 to 59.7/100,000 in 1952 
(Gottfried, 2005). Over this same 16-year period the life expectancy at birth increased an 
extraordinary 10.1 years, from 58.5 years in 1936 to 68.6 years in 1952 (Gottfried, 2005). 
This increase in the average life expectancy of Americans over that 16-year period is 
inevitably not entirely due to the rise of antibiotics in medical treatment. However, the effect 
of antibiotics was undeniably significant, especially when considering that in the 50 years 
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following 1952 the life expectancy at birth only increased another 8.7 years to 77.3 years by 
2002 (Gottfried, 2005).  
The implementation of penicillin and other antibiotics as a foundation of medical 
treatment has saved countless lives. However, recent developments in antibiotic resistance 
and a collapse in the development of new antibiotics have begun to threaten the worldwide 
effectiveness of antibiotic treatments. Many researchers worry that, unless things change 
soon, humans may soon be faced with a post-antibiotic era.  Shockingly, Dr. Fleming 
predicted this crisis a 1946 New York Times article when he stated: 
The public will demand [the drug]…then will begin an era…of abuses. The 
microbes are educated to resist penicillin and a host of penicillin-fast 
organisms is bred out which can be passed to other individuals and perhaps 
from there to others until they reach someone who gets a septicemia or a 
pneumonia which penicillin cannot save. In such a case the thoughtless person 
playing with penicillin treatment is morally responsible for the death of the 
man who formally succumbs to the infection with the penicillin-resistant 
organism. I hope this evil can be averted. (Fleming, 1946; Bartlett et al., 2013) 
 
Over 50 years ago Dr. Fleming warned against the evil of antibiotic abuse and the subsequent 
rise in antibiotic resistance. However, these warnings appeared to have fallen on deaf ears as 
today the public faces an undeniable global health crisis of rapidly increase antibiotic-
resistant bacteria coupled with an untimely and potentially devastating decrease in new 
antibiotic discovery and production.  
 
The Public Health Crisis  
The appearance of antibiotic-resistant bacteria is currently a major public health crisis 
that demands the attention of the scientific community. A 2016 report estimated that in the 
United States two million infections a year are caused by bacteria resistant to at least one 
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antibiotic (O’Neill, 2016). They approximated that the treatment of these antibiotic-resistant 
strains cost the US health care system 20 billion USD in excess costs (Medina and Pieper, 
2016).  A 2013 study found that at least 23,000 of these two million individuals die as a 
direct result of their antibiotic-resistant bacterial infections and many more die from 
complications induced by these bacteria (CDC, 2013). MRSA alone is responsible for almost 
11,285 deaths per year in the United States (Gross, 2013). Multiple studies estimated that 
worldwide 200,000 people a year die from multi-drug resistant strains of tuberculosis (TB) 
alone (Gross, 2013; CDC, 2013; RAR, 2016). A national survey of infectious disease 
specialists in 2011 found that 63% of the surveyed specialists had seen an untreatable 
bacterial infection resistant to all available antibiotics in the past year (Hersh et al., 2012 
Spellman and Gilbert, 2014). Author Ron Daniels writes that “increasing bacterial resistance 
to common antibiotics may put an ‘end to modern medicine as we know it’ (Daniels, 2012: 
11).  
This growing state of crisis at the hands of antibiotic-resistant bacteria is the result of 
an aggregation of several issues that combine to result in the overuse of antibiotics in the 
medical and agricultural industries. This overuse of antibiotics allows increased opportunity 
for antibiotic-resistant bacterial strains to flourish and multiply in antibiotic filled 
environments where their resistance-genes grant a selective fitness advantage. The first of 
these issues is the general over prescription and overuse of antibiotics in the medical field. 
Over prescription and overuse of antibiotics is a worldwide issue, however it is especially 
prevalent in the United States. Past research found that individuals in the US consumed an 
average of 22 antibiotic pills per year (Boeckel et al., 2010). In many states the number of 
prescribed courses of one antibiotic, whereas one course represents an entire antibiotic 
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treatment, exceeded the population (Gross, 2013; Ventola, 2015). Therefore in these sates 
individuals on average received more than one antibiotic treatment course per year. 
Worldwide the overuse of antibiotics is a worsening issue, with the worldwide antibiotic 
consumption increasing 36% in the ten-year period from 2000-2010 (Boeckel et al., 2010; 
Morrill and LaPlante, 2015). The issue of antibiotic overuse is exacerbated by the widespread 
inappropriate prescribing of antibiotic drugs. Research has found that up to 60% of the time 
doctors prescribe antibiotics they do so incorrectly, whether in situations when they are not 
needed or in incorrect doses (CDC, 2013; Luty et al., 2014; Lushniak, 2104). Incorrect 
dosages, especially when suboptimal, are an especially dangerous phenomenon. Sub-
therapeutic doses of antibiotics have been found to promote antibiotic resistance by 
stimulating genetic alterations in bacterial colonies through changes in gene expression, 
horizontal gene transfer and mutagenesis (Viswanatahn, 2013).  
While overuse and inappropriate prescription in medicine have contributed to the 
antibiotic-resistance crisis, the issue is especially amplified by the extensive use of antibiotics 
in the agricultural industry. Antibiotics have long been used by farmers to treat both their 
crops and livestock. Antibiotic treatment increases the overall health of the stock and crops 
and therefore the overall agricultural yield increases (Michael et al., 2014; Ventola, 2015). In 
total 15 million kilograms of antibiotics are used yearly in the United States, 80% in the 
agricultural sector (Bartlett et al., 2013’ Spellberg and Gilbert, 2014; Ventola, 2015). Recent 
research has shown that overuse of antibiotics in livestock can directly harm the humans 
consuming the meat of that livestock. First, antibiotic usage in the livestock kills non-
resistant bacterial strains and allows the resistant bacteria to thrive given the wealth of 
resources available after the non-resistant bacteria dies. Then, these antibiotic-resistant 
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bacteria are transferred to the humans who consume the meat of the livestock treated with 
excessive antibiotics. These antibiotic-resistant bacteria can than then cause serious 
infections in humans and be transmitted to other individuals from the initial host (CDC, 
2013; Ventola, 2015).  
 
The Current State of Antibiotic Drug Development  
It would seem logical that, given the immense importance of antibiotics in medicine 
and the continually worsening antibiotic resistance crisis, the investment in antibiotics 
research would currently be at a high point but this is simply not the case. Instead, the 
discovery of new antibiotics has essentially stalled and the financial investment in antibiotic 
discovery is shockingly low. Less than a decade ago researchers noted that there were 
currently no antibiotics in advanced development that successfully targeted bacteria already 
resistant to currently available antibiotics (Boucher et al., 2009). Two studies both note that 
all but five of the top 50 pharmaceutical companies have stopped funding antibiotics research 
entirely (Boucher, 2009; O’Neill, 2016). Of the largest 18 pharmaceutical companies, 15 had 
abandoned the antibiotic field by 2015 (Ventola, 2015). Overall, the researchers noted a 75% 
decrease in the antibiotics approved by the FDA from the period of 1983-2007 (Boucher, et 
al., 2009). They estimated the number of new FDA approved antibiotics will continue to drop 
as there has been a similar decrease in the number of registered early clinical trials for new 
antibiotics (Boucher, et al., 2009). Two recent studies found that only 40 antibiotics were 
currently in development and only 14 of those drugs were at or past phase 3 trials (Pew, 
2014; Lushniak, 2014). Dr. Lynn Silver, a leading expert on the antibiotic resistance crisis, 
exclaimed that we have suffered a “discovery void” of over 30 years where efforts to 
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research novel antibiotic classes have largely failed, “If you look at when things were 
discovered, we stopped discovering novel antibiotics in 1987” (Chemical Sciences 
Roundtable, 2014: 7).  
A significant cause for this precipitous drop in the discovery and success of novel 
antibiotics is financially motivated. Since Fleming and Waksman discovered the earliest 
antibiotics, a vast majority of antibiotic discovery has occurred due to the effort of large 
pharmaceutical companies. However, over the past thirty or so years multiple factors have 
combined to de-incentivize pharmaceutical research into novel antibiotic drugs. First, 
traditional approaches to discover new antibiotics have been largely unsuccessful over the 
past few decades and novel approaches have proved costly and time consuming (Davies, 
2006; Ventola, 2015). Also, stringent FDA clinical requirements oftentimes will take over 
ten years to approve a drug and therefore by the time of approval the 20-year patent for the 
drug is already halfway expired (Davies, 2006). Finally, the short and limited nature of 
antibiotic treatments, along with the relatively low cost of antibiotics in the market, result in 
antibiotics being a low profit drug (Davies, 2006; Ventola, 2015). Newer antibiotics are 
priced at a maximum of $1,000 to $3,000 per course, compared to newer chemotherapy 
drugs which can cost tens of thousands of dollars per course (Ventola, 2015). Also, drugs 
used to treat chronic disorders have a significantly longer course of treatment than 
antibiotics. Researcher Martin L. Katz notes that “whereas one patient might require a full 
year of therapy for a chronically administered drug…most antibiotic drugs are administered 
for about a week, and therefore, it would take 52 patients to achieve a similar financial 
return” (Katz et, 2006: 1530). Overall, a study by the London School of Economics found 
that a new antibiotic has a net present value of $-50 million, compared to a net present value 
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of +$1 billion for a new musculoskeletal drug (Ventola, 2015; Bartlett et al., 2013). The cost 
of research, development, production and approval often far surpasses the financial returns a 
pharmaceutical company will receive once the drug hits the market. All of this combines to 
form an environment where investment in antibiotic development and production is an 
unwise financial decision for pharmaceutical companies.  
 
Identifying Tryptophan Synthase as a Potential Antibiotic Target  
The research in this paper was motivated by the immense need for new antibiotics 
and the relative lack of antibiotic research and development in a time of dire need. Following 
extensive research, the enzyme tryptophan synthase was identified as a potential antibiotic 
target. Tryptophan synthase is an essential enzyme in bacteria, yeasts, molds and plants that 
catalyzes the formation of L-tryptophan from indole glycerol phosphate and L-serine (Miles, 
2009). Notably, although tryptophan synthase is necessary for the survival of bacteria it is not 
Fig. 1. The crystal secondary structure of wild type Salmonella typhimurium tryptophan 
synthase colored according to the subunits. Red = α-subunits, blue = β2 dimer (Schneider et 
al., 1998).  
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present in humans and other animals. Tryptophan synthase is composed of two α-subunits 
and one β2-dimer that combine to form a linear αββα complex (Miles, 2009; Fatimi et al., 
2009). The α subunit first catalyzes the reversible lyase of indoleglycerol phosphate (IGP) to 
an indole group (IND) and glyceraldehyde 3-phosphate (GAP) (Lane and Kirschner, 1991). 
The indole then travels through a 25 Å long hydrophobic tunnel that allows for direct 
substrate channeling from the α-active site to the β-active site (Fatimi et al., 2009; Barends et 
al., 2008).  The β2-dimer then catalyzes the irreversible synthesis of L-tryptophan from IND 
and L-serine (Lane and Kirschner, 1991). The secondary structure of tryptophan synthase can 
be seen in the image above (Schneider at al., 1998).  
The tryptophan produced from tryptophan synthase is essential for bacterial survival. 
While tryptophan is an essential amino acid that humans and other animals must consume 
through their diet, enzymatic production is the primary source of tryptophan in bacteria 
(Yanofsky, 2007). Tryptophan is an amino acid required for proper protein biosynthesis and 
many products of tryptophan, such as indole, are biologically essential compounds for 
bacteria (Yanofsky, 2007). Multiple studies have found that in E.coli the indole generated 
through tryptophan metabolism is involved in both cell-to-cell communication through 
quorum sensing and biofilm formation (Yanofsky, 2007; Wang et al., 2001; Ren et al., 2004; 
Winzer et al., 2002). Therefore, a significant lack of tryptophan should be fatal to bacterial 
cells. 
Since tryptophan is biologically essential for bacteria, the inhibition of bacterial 
enzymes involved in tryptophan biosynthesis have been suggested as potential drug targets 
(Dias et al., 2006; Chaudhary and Roos, 2005). Notably, all organisms that synthesize 
tryptophan endogenously do so by a single route and therefore inhibition of one enzyme in 
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the tryptophan biosynthesis pathway should significantly reduce intracellular tryptophan 
levels in bacteria (Dias et al., 2006). Past research briefly discussed the inhibition of 
tryptophan biosynthesis as a potential source for novel antibiotic enzymatic targets when 
discussing the genomic similarities between bacterial and protozoan tryptophan synthase 
(Chaudhary and Roos 2005). Later research specifically recommended tryptophan synthase 
as the most promising enzyme of the tryptophan biosynthesis pathway for the enzymatic 
target of potential antibiotics (Dias et al., 2006). These researchers noted that tryptophan 
synthase is the most extensively studied of the enzymes in the tryptophan synthesis pathway 
(Dias et al., 2006). In fact, earlier research observed that phosphonated inhibitors of 
tryptophan synthase are already being produced for their antimicrobial and herbicidal 
potential (Finn et al., 1999). Inhibitors of tryptophan synthase have already been found to be 
potentially successful broad-spectrum antibiotics (Faulkner et al., 2016).   
 Furthermore, previous research found that indole produced through tryptophan 
metabolism is directly involved in the expression of E. coli multidrug exporter genes 
(Hirakawa et al., 2005). These exporter genes are a common method of bacterial antibiotic 
multidrug resistance. The researchers found that in normal conditions these multidrug 
exporter genes are poorly expressed, however increased intracellular indole concentrations 
led to the overexpression of the exporter genes (Hirakawa et al, 2005). The amplified 
expression of the drug exporter genes, upregulated by the presence of indole, conferred 
multidrug resistance to E. coli colonies (Hirakawa et al., 2005). Inhibition of tryptophan 
synthase and the obstruction of tryptophan biosynthesis may therefore potentially prevent the 
multidrug resistance of E. coli and other bacteria with multidrug exporter genes.  
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Overall, the research suggests that tryptophan synthase is a promising target for 
antibiotic enzymatic inhibition. Not only may inhibition of tryptophan synthesis succeed as a 
broad-spectrum antibiotic target, but it also may act as an adjuvant, decreasing the potential 
for the development of resistance to other antibiotics. In fact, a recent study found that 5-
alkyloxytryptamines, tryptamine analogs from same base molecule as was utilized in this 
study, were successful both as broad-spectrum antibiotics and antibiotic adjuvants that 
potentiated the activity of current clinical antibiotics in Gram-positive and Gram-negative 
bacteria species (Faulkner et al., 2016). 
 
Tryptamine Analogs as Novel Antibiotics 
 Tryptamine has long been known as an inhibitor of bacterial tryptophan synthase. 
Research in the 1960’s discovered that tryptamine significantly decreased tryptophan 
synthase activity; at 500 µg/ml tryptamine completely inhibited tryptophan synthase activity 
in whole cells (Frendlich and Lichstein, 1961). Furthermore, these same researchers 
importantly found that tryptamine not only inhibited tryptophan synthase activity but also 
repressed the growth of E.coli cultures (Freundlich and Lichstein, 1961). Although these 
Fig. 2. Molecular structure of tryptamine.  
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study results showed that tryptamine and related molecules may be successful as potential 
antibiotics, little published research can be found on the topic in the preceding three decades.  
Over thirty years later researchers published a paper that identified Nematophin, a 
novel antibiotic from the soil microbe Xenorhabdus nematophilus (Jianxiong et al., 1997).	 
Nematophin was identified as a tryptamine analog and was found to be a highly active 
antibiotic against both wild-type and drug-resistant strains of S.aureus (Juanxiong et al., 
1997).		In the same paper these researchers also identified ten other Nematophin analogs, all 
of which were tryptamine analogs and displayed antibiotic properties, albeit weaker than the 
original nematophin (Jianxiong et al., 1997).  
Fifteen years later, different researchers published a paper that analyzed and 
identified a tryptamine-related antibiotic produced from the soil bacterium Intrasporangium 
N8 (Okudoh and Wallis, 2012). An earlier study by these same scholars found that the 
substance produced by the Intrasporangium was an antibiotic with significant antibacterial 
activity against both Gram-positive and Gram-negative bacteria (Okudoh and Wallis, 2007).		
Through the method of gas chromatography-mass spectroscopy (GC-MS) these investigators 
identified that one of four components in the antibiotic substance discovered in 2007 was N-
Fig. 3. Molecular structure of nematophin, a tryptamine analog antibiotic isolated from the 
soil microbe Xenorhabdus nematophilus (Jianxiong et al., 1997).  
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acetyltryptamine, a tryptamine analog (Okudoh and Wallis, 2012). Importantly, the 
researchers also noted that further research identified N-acetyltryptamine as the component 
responsible for the observed antibiotic qualities of the substance and that “the antibiotic 
produced by Intrasporangium strain N8 has the same or a similar mechanism of action to 
tryptamine” (Okudoh and Wallis, 2012: 737).  
A recent study continued this research into tryptamine analogs as potential antibiotic 
agents (Faulkner et al., 2016). They advanced earlier research by displaying that not only 
may tryptamine analogs be potentially successful broad-spectrum antibiotics, but they may 
also have applications as antibiotic adjuvants. Overall, the prior research has displayed 
serious potential for tryptamine analogs as successful broad-spectrum antibiotics and 
antibiotic adjuvants. However, the noticeable lack of tryptamine analogs currently in the 
pipeline for eventual FDA approval and production displays a need for the development of 
novel tryptamine analogs with antibiotic properties. The present work focuses on the 
development of novel tryptamine analogs and their potential use as novel antibiotics targeting 
the inhibition of the tryptophan synthase enzyme.  
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Materials and Methods 
Nomenclature and Identification System of the Tryptamine Analogs 
In order to clearly label and identify the tryptamine analogs we developed a 
nomenclature system of the original tryptamine molecule which labeled all of the non-
hydrogen atoms with the numbers 1-12. If the base atoms had multiple possible 
stereochemical orientations these different orientations were labeled a – b or a – d depending 
on the number available orientations. For the illustration of this nomenclature system we 
used ChemDraw Professional 16.0 to draw a diagram of the labeled atoms (PerkinElmer, 
2017). The labeled molecular diagram of the base tryptamine molecule is shown in Fig. 4.  
 
 
Fig. 4. Labeled molecular diagram of the base tryptamine molecule 
whereas all base atoms are labeled 1-12 and multiple possible 
stereochemical arrangements at a single base atom are labeled a-d.  
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Molecular Modeling of the Tryptamine 
Analogs   
 For modeling and design of the 
tryptamine analogs we used Visual 
Molecular Dynamics (VMD), a computer 
program for automated modeling and 
modification of molecules (Humphrey et al., 
1996). The crystal structure data of wild-
type tryptamine was used as the starting 
model (Nowell et al., 2002). The VMD 
Molecule Molefacture program was then 
used to replace specific hydrogens on the 
wild-type tryptamine molecule with one of 
four functional groups: amine, hydroxyl, 
methyl or carbonyl. In the first round of 
design each tryptamine analog only 
contained one of four functional groups 
attached to a numbered base atom in a 
specific stereochemical alignment. In 
situations where a single base atom had 
multiple available hydrogens to remove and 
replace, two of the same functional group 
were attached to that same base atom. The 
Fig. 5. Possible stereochemical orientations 
of tryptamine analogs with functional 
group addition at base atom 1 (White = 
hydrogen, Teal = Carbon, Red = Oxygen, 
Blue = Nitrogen). (A) 1a; (B) 1b; (C) 1(2). 
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possible stereochemical orientations of additions to the nitrogen at base atom 1 are seen in 
Fig. 5. The stereochemical alignments of the groups attached to the nitrogen were identical 
across the other three functional groups. When performing modification on the carbons at 
base atoms 2 and 3, there were four different stereochemical orientations for additions of a 
single functional group and two unique stereochemical orientations for addition of two of the 
same functional group. The possible stereochemical alignments of functional groups attached 
at carbon 3 are seen in Fig. 6. These stereochemical orientations are consistent across all 
Fig. 6. Possible stereochemical orientations of tryptamine analogs with a 
functional group addition at base atom 3 (White = hydrogen, Teal = Carbon, 
Red = Oxygen, Blue = Nitrogen). (A) 3a; (B) 3b; (C) 3c; (D) 3d; (E) 3(2)a; (F) 
3(2)b.  
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other functional groups and at both of the carbons at positions two and three. Finally, 
additions at the carbons along the indole ring, at locations 5 and 9-12 only occurred in a 
single stereochemical orientation. A second round of tryptamine analogs with multiple 
functional groups attached at multiple different numbered base atoms were created soon after 
the analysis of the initial binding affinity data and followed the same identification system. In 
total, seventy-two unique tryptamine analogs were created through this process.  
 
Binding Affinity Analysis of Tryptophan Synthase Subunits-Tryptamine Analogs 
Complexes 
For the binding affinity analyses of the complexes between the tryptophan synthase 
subunits and tryptamine analogs we used PyRx, a computer program for screening libraries 
of compounds against potential drug targets (Dallakyn and Olson, 2015). Three separate 
crystal structures of tryptophan synthase were utilized in this study: the structures of the α-
subunit and the β2-dimer of E. coli tryptophan synthase and the β2-dimer of M.tuberculosis 
(Nishio et al., 2015; Nishio et al., 2016; Kachalova et al.). For the three enzyme crystal 
structures we used the PDB access codes: 1V7Y, 2DH5 and 2O2E respectively. In order to 
simulate the protein-ligand complexes between the tryptophan synthase subunits and 
tryptamine analogs the crystal structures of the E. coli α-subunit and the E. coli and 
M.tuberculosis β2-dimers were loaded directly into the PyRx program. First, before the 
protein-ligand complexes were formed, all 72 of the tryptamine analogs and wild-type 
tryptamine were energetically minimized using the PyRx program. After the minimization 
process was completed we used the PyRx software to simulate the formation of the protein-
ligand complexes between the tryptophan synthase subunits and the tryptamine analogs. For 
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all three tryptophan synthase subunits the entire macromolecule was selected as a potential 
binding region for the tryptamine analogs. All potential binding interactions between the 
tryptophan synthase subunits and each individual tryptamine analog, including wild-type 
tryptamine, were then simulated. Estimates of the nine strongest binding affinities (kcal/mol) 
for each protein-ligand complex were provided by PyRx. The binding affinities were 
presented as negative values and the more negative the kcal/mol value the stronger the 
binding affinity between the protein-ligand complex. An increase in binding affinity of – 1 
kcal/mol correlated to an approximately ten-fold increase in the binding affinity between the 
protein and the ligand. Between the 72 tryptamine analogs, wild-type tryptamine and three 
tryptophan synthase subunits, 219 unique protein-ligand complexes were modeled and 1,971 
binding affinity measurements were taken. The strongest binding affinity for each protein-
ligand complex was then separated and we graphed the results using the computer program R 
and the package ggplot2 (R Core Team, 2016; Wickham, 2009).  
 
Binding Affinity Analysis of Human MAOB-Tryptamine Analogs Complexes 
For the binding affinity analyses of the complexes between human MAOB and the 
tryptamine analogs we used PyRx again (Dallakyn and Olson, 2015). The crystal structure of 
human MAOB, PDB access code 1GOS, was used as the enzymatic model for MAOB 
(Binda et al., 2001). The human MAOB crystal structure and the already energetically 
minimized wild-type tryptamine and tryptamine analogs were loaded directly into PyRx. 
Then, we used the PyRx software to simulate the formation of protein-ligand complexes 
between the MAOB enzyme and the tryptamine molecules. Again, the entire MAOB enzyme 
was selected as a potential binding region for the tryptamine analogs. Estimates of the nine 
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strongest binding affinities (kcal/mol) for the MAOB-wild-type tryptamine complex and each 
of the 72 MAOB-tryptamine analog complexes were provided by PyRx. The strongest 
binding affinity value for each complex was then separated and we again graphed the results 
using the computer program R and the package ggplot 2 (R Core Team, 2016; Wickham, 
2009).   
 
Molecular Modeling of Complexes Between Tryptophan Synthase Subunits or Human 
MAOB and Identified Tryptamine Analogs Complexes 
For the modeling of the protein-ligand complexes between the tryptophan synthase 
subunits or human MAOB and the ten identified tryptamine analogs we used the program 
PyMOL (Schrödinger). Following the binding affinity analyses the protein-ligand complexes 
formed in PyRx were exported to PyMOL. Within PyMOL the location the ten tryptamine 
analogs bound to the surface of the tryptophan synthase subunits or human MAOB with the 
highest binding affinity was visualized and analyzed. The number of hydrogen bonds that 
each tryptamine analog formed with the enzyme of question was determined. Pictures of the 
binding sites and hydrogen bond formations were taken for each protein-ligand complex that 
the ten identified tryptamine analogs formed. This process was then repeated with the 
complexes formed by wild-type tryptamine and the tryptophan synthase subunits and human 
MAOB. The binding regions and hydrogen bond formation of the tryptamine analogs were 
then compared to wild-type tryptamine for each of the four enzymatic targets. 
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Results  
Binding Affinity Analysis of Tryptophan Synthase Subunits-Tryptamine Analogs 
Complexes  
Line plots were generated containing the highest binding affinity value of each 
tryptamine analog to the E. coli α-subunit. These values were compared to the binding 
affinity of wild-type tryptamine to the E. coli α-subunit. The plot of the binding affinities of 
wild-type tryptamine and the tryptamine analogs to the E. coli α-subunit is presented in Fig. 
7. Almost every tryptamine analog had a higher binding affinity to the E. coli α-subunit than 
Fig. 7. Comparison between the binding affinities (kcal/mol) of the tryptamine analogs and 
the E. coli tryptophan synthase α-subunit to the binding affinity of wild-type tryptamine and 
the same subunit. The red arrows identify the ten tryptamine analogs identified for further 
research. 
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wild-type tryptamine, however ten tryptamine analogs displayed a noticeably larger increase 
in binding affinity than the others.  
Line plots were then produced containing the highest binding affinity value of each 
tryptamine analog to the E. coli β2 dimer. The binding affinities of the tryptamine analogs 
were compared to the binding affinity of wild-type tryptamine to the E. coli β2 dimer. The 
plot of the binding affinities of wild-type tryptamine and the tryptamine analogs to the E. coli 
β2 dimer is presented in Fig. 8. The binding affinity of wild-type tryptamine to the E. coli β2 
dimer was significantly stronger than the wild-type binding affinity to the E. coli α-subunit 
and therefore many of the tryptamine analogs weakened the binding affinity to the E. coli β2 
Fig. 8. Comparison between the binding affinities (kcal/mol) of the tryptamine analogs and 
the E. coli tryptophan synthase β2-dimer to the binding affinity of wild-type tryptamine and 
the same subunit. The red arrows identify the ten tryptamine analogs identified for further 
research. 
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dimer. However, once again there were several tryptamine analogs that displayed an 
increased binding affinity to the E. coli β2 dimer. The ten analogs identified in the past 
section all exhibited a greater binding affinity to the E. coli β2 dimer than wild-type 
tryptamine, although in same cases other analogs caused an even greater increase in binding 
affinity.  
A third line plot was created containing the highest binding affinity value of each 
tryptamine analog to the M. tuberculosis β2 dimer. As before, the binding affinities of the 
tryptamine analogs were compared to the binding affinity of wild-type tryptamine to the M. 
tuberculosis β2 dimer. This plot of the binding affinities of wild-type tryptamine and the 
tryptamine analogs to the M. tuberculosis β2 dimer is presented in Fig. 9. The clear majority 
Fig. 9. Comparison between the binding affinities (kcal/mol) of the tryptamine analogs and 
the M. tuberculosis tryptophan synthase β2-dimer to the binding affinity of wild-type 
tryptamine and the same subunit. The red arrows identify the ten tryptamine analogs 
identified for further research. 
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of tryptamine analogs displayed a significantly stronger binding affinity to the M. 
tuberculosis β2 dimer than wild-type tryptamine. Again, although a few other analogs 
demonstrated a greater increase in their binding affinities to the M. tuberculosis β2 dimer, the 
ten analogs identified earlier showed a significant increase in binding affinities to the M. 
tuberculosis β2 dimer. 
To quantify the potential of the tryptamine analogs as broad-spectrum antibiotic 
agents we calculated each analog’s relative change from wild-type tryptamine in binding 
affinity to each of the three tryptophan synthase subunits. These three values were then added 
together to ascertain each tryptamine analogs’ combined increase in relative binding affinity 
to the tryptophan synthase subunits. The plot of each analog’s combined relative change from 
Fig. 10. Summation of the relative differences between the binding affinities (kcal/mol) of the 
tryptamine analogs and wild-type tryptamine to the three tryptophan synthase subunits used in 
this paper. The red arrows identify the ten tryptamine analogs identified for further research. 
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wild-type tryptamine in binding affinity to the three bacterial tryptophan synthase subunits is 
presented in Fig.10. Several tryptamine analogs displayed a decrease from wild-type 
tryptamine in the combined binding affinity to the three tryptophan synthase subunits. 
However, a definite majority demonstrated an increase in the combined binding affinity to 
the tryptophan synthase subunits when compared to wild-type tryptamine. Noticeably, the ten 
tryptamine analogs identified in the earlier sections displayed the largest increases in the 
combined relative binding affinity.  
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Binding Affinity Analysis of Human MAOB-Tryptamine Analogs Complexes 
After testing the effect of the tryptamine modifications on the molecules’ binding 
affinities to bacterial tryptophan synthase, we utilized similar methods to test the effects of 
the same modifications on the tryptamine analogs’ binding affinity to human MAOB. Line 
plots were produced containing the highest binding affinity value of each tryptamine analog 
to the human MAOB. Then, we compared the binding affinities of the tryptamine analogs to 
human MAOB and the binding affinity of wild-type tryptamine to human MAOB.  The plot 
of the binding affinities of wild-type tryptamine and the tryptamine analogs to human MAOB 
is presented in Fig. 11. In an attempt to visualize the differences in binding affinities to 
human MAOB between the tryptamine analogs and wild-type tryptamine we created a graph 
of each analog’s relative difference from wild-type tryptamine in MAOB binding affinity, 
Fig. 11. Comparison between the binding affinities (kcal/mol) of the tryptamine analogs and 
human MAOB to the binding affinity of wild-type tryptamine to MAOB. The red arrows 
identify the ten tryptamine analogs identified for further research. 
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seen in Fig.12. Although a few tryptamine analogs were able to decrease the binding affinity 
to human MAOB, a significant majority displayed an increased MAOB binding affinity 
when compared to wild-type tryptamine. Similarly, all ten of the promising tryptamine 
analogs showed an increased human MAOB binding affinity. However, the one tryptamine 
analog that involved the addition of an amine group, and not a hydroxyl group, displayed the 
smallest MAOB binding affinity increase of the ten identified molecules. 
 
 
 
 
Fig. 12. The relative difference in the binding affinity (kcal/mol) to MAOB of the 
tryptamine analogs from wild-type tryptamine. The red arrows identify the ten tryptamine 
analogs identified for further research. 
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Integrating the Tryptamine Analogs’ Binding Affinities to Tryptophan Synthase and 
MAOB 
Finally, we designed an analysis to integrate both the tryptamine analogs’ binding 
affinities to the three tryptophan synthase subunits and the analogs’ binding affinities to the 
human MAOB. To accomplish this, we subtracted the relative difference in binding affinity 
to MAOB between the tryptamine analogs and wild-type tryptamine from the summated 
relative difference in binding affinity to the tryptophan synthase subunits between the 
tryptamine analogs and wild-type tryptamine. The plot of this difference in relative binding 
affinities is presented in Fig. 14. Overall, a majority of tryptamine analogs had a positive 
difference in the relative binding affinity change from wild-type between the tryptophan 
synthase subunits and human MAOB. Significantly, the ten aforementioned tryptamine 
analogs displayed the highest differences in relative binding affinity.  
Fig. 13. The difference between the combined increase in relative binding affinity 
(kcal/mol) of the tryptamine analogs from wild-type tryptamine to the three tryptophan 
synthase subunits and the relative difference in the binding affinity of the tryptamine 
analogs from wild-type tryptamine to human MAOB. The red arrows identify the ten 
tryptamine analogs identified for further research. 
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Identification of the Tryptamine Analogs Deserving Synthesis and Further Research 
 Following the extensive binding affinity analyses, we identified ten tryptamine 
analogs that present the most promise as tryptophan synthase inhibitors. The molecular 
structure of these ten tryptamine analogs are pictured in Fig. 14. Nine of the most promising 
tryptamine analogs included additions of one, or multiple, hydroxyl functional groups and the 
tenth resulted from an addition of two amine groups at the carbon at position two. Of the nine 
identified tryptamine analogs involving the addition of a hydroxyl group, one had only a 
single hydroxyl group addition while the other eight resulted from the addition of multiple 
hydroxyl groups at one, or several different, base atoms. 
Several of the tryptamine analogs generated by the VMD program possess a 
significantly stronger binding affinity than wild-type tryptamine to each of the three 
tryptophan synthase subunits. Furthermore, when compared with wild-type tryptamine, the 
ten most promising tryptamine analogs display an increase of 1.8 kcal/mol – 3.9 kcal/mol in 
combined relative binding affinity across the three tryptophan synthase subunits. The 
increases in tryptophan synthase subunit binding affinities for 1(2)+(2)b+10+11+12 hydroxyl 
tryptamine molecule, the analog that exhibited the largest combined increase in relative 
binding affinity, correlated to an approximately 14 times increase in the binding affinity to E. 
coli tryptophan synthase α-subunit, a 9 times increase to the E. coli β2-dimer and a 16 times 
increase to the M. tuberculosis β2-dimer.  
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Fig. 14. Molecular structures of the ten most promising 
tryptamine analogs identified through binding affinity 
analyses. (A) 1(2) hydroxyl; (B) 2b hydroxyl; (C) 2(2)b 
hydroxyl; (D) 2(2)b amine; (E) 3(2)b hydroxyl;             (F) 
1(2)+(2)b hydroxyl; (G) 1(2)+(2)b+11 hydroxyl;                    
(H) 1(2)+(2)b+11+12 hydroxyl; (I) 1(2)+(2)b+10+11+12 
hydroxyl; (J) 1(2)+(2)b+9+10+11+12 hydroxyl. 
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Molecular Modeling of Complexes Between Tryptophan Synthase Subunits or Human 
MAOB and Identified Tryptamine Analogs Complexes 
 
 
 
Fig. 15. Molecular models of the strongest binding interactions of the E.coli tryptophan 
synthase α-subunit (purple) and (WT) wild-type tryptamine, (A) 1(2) hydroxyl, (B) 2b 
hydroxyl, (C) 2(2)b hydroxyl, (D) 2(2)b amine, (E) 3(2)b hydroxyl, (F) 1(2)+(2)b 
hydroxyl, (G) 1(2)+(2)b+11 hydroxyl, (H) 1(2)+(2)b+11+12 hydroxyl, (I) 
1(2)+(2)b+10+11+12 hydroxyl and (J) 1(2)+(2)b+9+10+11+12 hydroxyl. Yellow 
numbers represent the number of hydrogen bonds in the binding interaction.  
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After ten tryptamine analogs were identified through the binding affinity analyses we 
modeled the strongest binding interaction of these ten tryptamine analogs to the E. coli 
tryptophan synthase α-subunit. Within this model we visualized the number of hydrogen 
bonds that each tryptamine analog formed with the α-subunit. The pictures of the strongest 
binding interaction for the ten identified tryptamine analogs, including the hydrogen bonds 
formed, is presented in Fig. 15. None of the ten identified tryptamine analogs bound with the 
highest affinity to the same region of the α-subunit as wild-type tryptamine. Furthemore, 
there was large variance in the the area of strongest binding affinity between the tryptamine 
analogs. In total we observed five general regions of the α-subunit where one or more of the 
tryptamine analogs bound with the highest affinity. However, when compared with wild-type 
tryptamine, a majority of the tryptamine analogs increased the number of hydrogen bonds 
formed with the α-subunit. Only one analog decreased the number of hydrogen bonds formed 
with the α-subunit.  
We then modeled the strongest binding interaction of the ten identified tryptamine 
analogs to the E.coli tryptophan synthase β2-dimer. Within this model we visualized the 
number of hydrogen bonds that each tryptamine analog formed with the β2-dimer. The 
pictures of the tryptamine analogs’ strongest binding interactions with the E. coli β2-dimer, 
including the hydrogen bonds formed, is presented in Fig. 16. While there was some 
variation in the orientation of binding, all ten of the identified tryptamine analogs bound with 
the highest affinity to the same region of the β2-dimer as wild-type tryptamine. Also, a 
majority of the tryptamine analogs increased the number of hydrogen bonds formed with the 
E. coli β2-dimer. No analogs decreased the number of hydrogen bonds formed with the α-
subunit. 
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Following the modeling of both E. coli tryptophan synthase subunits we modeled the 
strongest binding interaction of the ten identified tryptamine analogs to the M. tuberculosis 
tryptophan synthase β2-dimer. We also vizualized the number of hydrogen bonds that each 
tryptamine analog formed with the β2-dimer. The pictures of the tryptamine analogs’ 
Fig. 16. Molecular models of the strongest binding interactions of the E.coli tryptophan 
synthase β2-dimer (blue) and (WT) wild-type tryptamine, (A) 1(2) hydroxyl, (B) 2b 
hydroxyl, (C) 2(2)b hydroxyl, (D) 2(2)b amine, (E) 3(2)b hydroxyl, (F) 1(2)+(2)b hydroxyl, 
(G) 1(2)+(2)b+11 hydroxyl, (H) 1(2)+(2)b+11+12 hydroxyl, (I) 1(2)+(2)b+10+11+12 
hydroxyl and (J) 1(2)+(2)b+9+10+11+12 hydroxyl. Yellow numbers represent the number 
of hydrogen bonds in the binding interaction.  
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strongest binding interactions with the M. tuberculosis β2-dimer, including the hydrogen 
bonds formed, is presented in Fig. 17. Again, while there were slight discrepancies in the 
orientation of binding, all ten of the identified tryptamine analogs bound with the highest 
affinity to the same region of the M. tuberculosis β2-dimer as wild-type tryptamine. Also, 
Fig. 17. Molecular models of the strongest binding interactions of the M. tuberculosis 
tryptophan synthase β2-dimer (green) and (WT) wild-type tryptamine, (A) 1(2) hydroxyl, 
(B) 2b hydroxyl, (C) 2(2)b hydroxyl, (D) 2(2)b amine, (E) 3(2)b hydroxyl, (F) 1(2)+(2)b 
hydroxyl, (G) 1(2)+(2)b+11 hydroxyl, (H) 1(2)+(2)b+11+12 hydroxyl, (I) 
1(2)+(2)b+10+11+12 hydroxyl and (J) 1(2)+(2)b+9+10+11+12 hydroxyl. Yellow 
numbers represent the number of hydrogen bonds in the binding interaction.  
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nearly all of the tryptamine analogs increased the number of hydrogen bonds formed with the 
M. tuberculosis β2-dimer. Again, no analogs decreased the number of hydrogen bonds 
formed with the β2-dimer. 
Finally, we modeled the strongest binding interaction of the ten identified tryptamine 
analogs to human MAOB. We also vizualized the number of hydrogen bonds that each 
Fig. 18. Molecular models of the strongest binding intereactions of the human 
MAOB (red) and (WT) wild-type tryptamine, (A) 1(2) hydroxyl, (B) 2b hydroxyl, 
(C) 2(2)b hydroxyl, (D) 2(2)b amine, (E) 3(2)b hydroxyl, (F) 1(2)+(2)b hydroxyl, 
(G) 1(2)+(2)b+11 hydroxyl, (H) 1(2)+(2)b+11+12 hydroxyl, (I) 
1(2)+(2)b+10+11+12 hydroxyl and (J) 1(2)+(2)b+9+10+11+12 hydroxyl. Yellow 
numbers represent the number of hydrogen bonds in the binding interaction.  
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tryptamine analog formed with MAOB. The pictures of the tryptamine analogs’ strongest 
binding interactions with the human MAOB, including the hydrogen bonds formed, is 
presented in Fig. 18. Again, while were slight differences in the orientation of binding, all ten 
of the identified tryptamine analogs bound with the highest affinity to the same region of 
human MAOB as wild-type tryptamine. Exactly half of the tryptamine analogs increased the 
number of hydrogen bonds formed with human MAOB. Two of the analogs decreased the 
number of hydrogen bonds formed with human MAOB. 
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Discussion 
In silico molecular modeling enabled us to model novel tryptamine analogs and 
analyze the effects of various functional group additions on the molecules’ binding affinities 
to the following tryptophan synthase subunits: E. coli α-subunit, E. coli β2-dimer and the M. 
tuberculosis β2-dimer. This same molecular modeling process allowed us to determine the 
effects of these same functional group additions on the molecules’ binding affinities to 
human MAOB. Furthermore, we were able to analyze the location on the enzymes where the 
ten identified tryptamine analogs bind with the highest affinity. Our research found that 
additions of certain functional groups to wild-type tryptamine can significantly increase the 
molecules’ tryptophan synthase binding affinities. However, despite the successes in 
increasing the tryptophan synthase binding affinity in the tryptamine analogs, we could not 
model any tryptamine-like molecules that both increased tryptophan synthase binding affinity 
while also decreasing the human MAOB binding affinity. Instead, the ability of the 
tryptamine analogs to bind to tryptophan synthase was correlated with their ability to bind to 
human MAOB. This may suggest that tryptophan synthase and human MAOB have similar 
tryptamine binding sites.  
From the molecular modeling of binding regions, we found that the ten tryptamine 
analogs bind with the highest affinity to the same region as wild-type tryptamine in the E. 
coli tryptophan synthase β2-dimer, the M. tuberculosis β2-dimer and human MAOB. 
However, to the E. coli tryptophan synthase α-subunit the ten tryptamine analogs bind with 
the highest affinity to a different region than wild-type tryptamine and there is variance in α-
subunit binding regions across the tryptamine analogs. Compared to wild-type tryptamie, the 
majority of the tryptamine analogs display an increase in the number of hydrogen bonds they 
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form when bound to the three tryptophan synthase subunits, while only a small number 
decrease the number of hydrogen bonds in the binding interactions. In the E. coli α-subunit 
one analog increases the number of hydrogen bonds 3.5x compared to wild-type tryptamine, 
in the E. coli β2-dimer the highest hydrogen bond increase is 4x, and in the M. tuberculosis 
β2-dimer the greatest hydrogen bond increase is 8x. Similar to the binding affinity assays, 
half of the tryptamine analogs also display an increase in the number of hydrogen bonds they 
form with human MAOB when compared to wild-type tryptamine. The other half of the 
analogs either exhibited the same or a decreased number of hydrogen bonds to human 
MAOB.  
Regardless of the increase in human MAOB binding affinity and an increase in 
hydrogen bonding to MAOB in half of the analogs, the identified tryptamine analogs show 
promise as tryptophan synthase inhibitors and subsequently, as novel broad-spectrum 
antibiotics. Earlier studies have shown that tryptamine and tryptamine-like analogs are 
potentially successful antibiotics through their inhibition of bacterial tryptophan synthase 
(Freundlich and Lichestein, 1961; Jianxiong et al., 1997; Okudoh and Wallish, 2012; 
Faulkner et al., 2016). Our research supports and augments this earlier research by showing 
that additions of certain functional groups can significantly increase the tryptophan synthase 
binding affinity, and therefore the molecules’ potential as tryptophan synthase inhibitors. 
Specifically, our data identifies ten potential tryptamine analogs that provide a significant 
increase from wild-type tryptamine in the bacterial tryptophan synthase binding affinity.  
Multiple studies have noted that tryptamine has a high turnover rate in mammalian 
brains because of MAO-catalyzed oxidative deamination (Yu, 1985; Sullivan et al., 1986). 
Therefore, the correlated increase in human MAOB binding affinity alongside the increases 
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in tryptophan synthase binding affinity may affect the potential effectiveness of tryptamine 
analogs as clinical antibiotic agents. However, further research is required before the effects 
of MAO on a tryptamine analog antibiotics can be determined. Although the strong MAOB 
binding affinity of the tryptamine analogs may harm their antibiotic effects, it may introduce 
another potential pharmaceutical capability. Research has found that certain tryptamine 
analogs are successful MAO inhibitors in vivo (Balsa et al., 1990; Avila et al., 1993). 
Therefore, given their significant increase in human MAOB binding affinity, the tryptamine 
analogs identified in this paper display potential as MAO inhibitors. MAO inhibitors are 
important drugs, utilized in the treatment of Parkinson’s disease and other neurological 
disorders. Moving forward, future research should be dedicated to determining the 
effectiveness of the tryptamine analogs as MAO inhibitors in vivo.  
While the tryptamine analogs’ potential use as MAO inhibitors is both interesting and 
intriguing, the primary findings of our paper consists of the identification of ten tryptamine 
analogs with significant prospects as tryptophan synthase inhibitors and therefore as broad-
spectrum antibiotic agents. When compared to wild-type tryptamine, the ten tryptamine 
analogs exhibited an approximately 18 to 39 times increase in the combined relative binding 
affinity across the three tryptophan synthase subunits tested in this study. Furthermore, 
although there was a correlation between increases in both the tryptophan synthase and 
MAOB binding affinities, this was not a 1:1 relationship. Instead, our identified tryptamine 
analogs displayed a much greater increase in tryptophan synthase subunit binding affinity 
than in MAOB binding affinity. The analogs’ increases in hydrogen bond formation to the 
tryptophan synthase subunits when compared to wild-type tryptamine also supports the 
quantitative increases in binding affinity because increasing hydrogen bonding interactions 
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should increase the binding affinity of the protein-ligand complex. This data indicates 
significant potential for in vivo tryptophan synthase inhibition. Significantly increased 
binding affinities to the tryptophan synthase subunits may correlate to increased inhibition of 
the tryptophan synthase enzyme and subsequently increased antibiotic capabilities.  
Additionally, the similarities in binding sites to the E. coli and M. tuberculosis β2-
dimers between wild-type tryptamine and the tryptamine analogs provide further evidence 
towards the analogs’ potential as tryptophan synthase inhibitors and antibiotic agents. The 
similarities in binding region suggest that the tryptamine analogs will have a similar 
inhibitory effect on tryptophan synthase as wild-type tryptamine. However, the analogs did 
bind to different regions on the E. coli α-subunit than wild-type tryptamine. While these 
differences in binding sites may affect the functionality of the tryptamine analogs, this cannot 
be guaranteed until the analogs are synthesized and tested further.  
Following this research, we filed a provisional patent on the novel structures of the 
ten identified tryptamine analogs. If these tryptamine analogs are successful as tryptophan 
synthase inhibitors, as the in silico data suggests, they may succeed as antibiotic agents. 
Consequently, these novel molecules may provide new antibiotic drugs to combat the 
growing global health crisis of antibiotic resistance and help fill the discovery void of the 
past three decades. Furthermore, given past research that identified tryptophan synthase 
inhibitors as potential antibiotic adjuvants, these tryptamine molecules may also facilitate the 
success of other clinical antibiotics (Hirakawa et al., 2004). Therefore, we propose that the 
ten tryptamine analogs presented in Fig. 14 are deserving of synthesis and further in vitro and 
in vivo research into their antibiotic properties.  
 
 
	
46 
Works Cited 
Avila, M., Balsa, M.D., Fernandez-Alvarez, E., Tipton, K.F., and Unzeta, M. (1993). The 
effect of side chain substitution at positions 2 and 3 of the heterocyclic ring of N-
acetylenic analogues of tryptamine as monoamine oxidase inhibitors. Biochemical 
Pharmacology 45, 2231–2237. 
Balsa, D., Fernandez-Alvarez, E., Tipton, K.F., and Unzeta, M. (1990). Inhibition of MAO 
by substituted tryptamine analogues. In Amine Oxidases and Their Impact on 
Neurobiology, (Springer, Vienna), pp. 103–105. 
Barends, T.R.M., Dunn, M.F., and Schlichting, I. (2008). Tryptophan synthase, an allosteric 
molecular factory. Curr Opin Chem Biol 12, 593–600. 
Bartlett, J.G., Gilbert, D.N., and Spellberg, B. (2013). Seven Ways to Preserve the Miracle of 
Antibiotics. Clin Infect Dis 56, 1445–1450. 
Bax, R., and Griffin, D. (2012). Introduction to Antibiotic Resistance. 1–12. 
Binda, C., Newton-Vinson, P., Hubálek, F., Edmondson, D.E., and Mattevi, A. (2002). 
Structure of human monoamine oxidase B, a drug target for the treatment of 
neurological disorders. Nat Struct Mol Biol 9, 22–26. 
Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheld, 
M., Spellberg, B., and Bartlett, J. (2009). Bad Bugs, No Drugs: No ESKAPE! An 
Update from the Infectious Diseases Society of America. Clin Infect Dis 48, 1–12. 
Brown, P.D. (2010). Multiple Drug Resistance. In Multiple Drug Resistance, (Nova Science 
Publishers Inc.),. 
CDC (2013). Antibiotic Resistance Threats in the United States, 2013 (US Department of 
Health and Human Services). 
Chaudhary, K., and Roos, D.S. (2005). Protozoan genomics for drug discovery. Nat Biotech 
23, 1089–1091. 
Chemical Sciences Roundtable. (2014). Technological Challenges in Antibiotic Discovery 
and Development: : A Workshop Summary. The National Academies Press.  
Dallakyan, S., and Olson, A.J. (2015). Small-molecule library screening by docking with 
PyRx. Methods Mol. Biol. 1263, 243–250. 
Daniels, R. (2012). Antibiotic resistance: a crisis in the making. Emergency Nurse 20, 11–11. 
Davies, J. (2006). Where have  All the Antibiotics Gone? Can J Infect Dis Med Microbiol 17, 
287–290. 
Davies, J., and Davies, D. (2010). Origins and Evolution of Antibiotic Resistance. Microbiol 
Mol Biol Rev 74, 417–433. 
Dias, M.V.B., Canduri, F., Silveira, N.J.F. da, Czekster, C.M., Basso, L.A., Palma, M.S., 
Santos, D.S., and Azevedo, W.F. de (2006). Molecular models of tryptophan synthase 
 
	
47 
from Mycobacterium tuberculosis complexed with inhibitors. Cell Biochem Biophys 
44, 375–384. 
Fatmi, M.Q., Ai, R., and Chang, C.A. (2009). Synergistic Regulation and Ligand-Induced 
Conformational Changes of Tryptophan Synthase. Biochemistry 48, 9921–9931. 
Faulkner, K.C., Hurley, K.A., and Weibel, D.B. (2016). 5-Alkyloxytryptamines are 
membrane-targeting, broad-spectrum antibiotics. Bioorganic & Medicinal Chemistry 
Letters 26, 5539–5544. 
Finn, J., Langevine, C., Birk, I., Birk, J., Nickerson, K., and Rodaway, S. (1999). Rational 
herbicide design by inhibition of tryptophan biosynthesis. Bioorganic & Medicinal 
Chemistry Letters 9, 2297–2302. 
Fleming, A. (1945). Penicillin. 
Fleming, A. (1946). Penicillin’s finder assays its future. New York Times. 
Freundlich, M., and Lichstein, H.C. (1962). TRYPTOPHANASE-TRYPTOPHAN 
SYNTHETASE SYSTEMS IN ESCHERICHIA COLI I. J Bacteriol 84, 979–987. 
Gottfried, J. (2005). History Repeating? Avoiding a Return to the Pre-Antibiotic Age. Third 
Year Paper. Harvard Law School. 
Gross, M. (2013). Antibiotics in crisis. Current Biology 23, R1063–R1065. 
Hersh, A.L., Newland, J.G., Beekmann, S.E., Polgreen, P.M., and Gilbert, D.N. (2012). 
Unmet Medical Need in Infectious Diseases. Clin Infect Dis 54, 1677–1678. 
Hirakawa, H., Inazumi, Y., Masaki, T., Hirata, T., and Yamaguchi, A. (2005). Indole induces 
the expression of multidrug exporter genes in Escherichia coli. Molecular 
Microbiology 55, 1113–1126. 
Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD - Visual Molecular Dynamics. H 
Molec. Graphics 14, 33–38. 
Jianxiong, L., Genhui, C., and Webster, J.M. (1997). SYNTHESIS AND 
ANTISTAPHYLOCOCCAL ACTIVITY OF NEMATOPHIN AND ITS ANALOGS. 
Bioorganic & Medicinal Chemistry Letters 7, 1349–1352. 
Kachalova, G.S., Burenkov, G.P., Strizhov, I.N., Svergun, I.D., and Bartunik, H.D. (To Be 
Published). Structure Tryptophan Synthase beta subunit dimer from Mycobacterium 
Tuberculosis. 
Katz, M.L., Mueller, L.V., Polyakov, M., and Weinstock, S.F. (2006). Where have all the 
antibiotic patents gone? Nat Biotech 24, 1529–1531. 
Lushniak, B.D. (2014). Antibiotic Resistance: A Public Health Crisis. Public Health Reports 
129, 314–316. 
Luyt, C.-E., Bréchot, N., Trouillet, J.-L., and Chastre, J. (2014). Antibiotic stewardship in the 
intensive care unit. Critical Care 18, 480. 
 
	
48 
Manfredi, R. (2009). The Phenomenon of Antibiotic Resistance in an Evolutionary 
Perspective. In Antibiotic Resistance : Causes and Risk Factors, Mechanisms and 
Alternatives,. 
Medina, E., and Pieper, D.H. (2016). Tackling Threats and Future Problems of Multidrug-
Resistant Bacteria. 3–33. 
Miles, E.W. (2009). Tryptophan Synthase: Structure, Function and Subunit Interaction. In 
Advances in Enzymology and Related Areas of Molecular Biology, (John Wiley & 
Sons),. 
Morrill, H.J., and LaPlante, K.L. (2015). Overconsumption of antibiotics. The Lancet 
Infectious Diseases 15, 377–378. 
Neu, H.C. (1992). The Crisis in Antibiotic Resistance. Science 257, 1064–1073. 
Nishio, K., Morimoto, Y., Ishizuka, M., Ogasahara, K., Tsukihara, T., and Yutani, K. (2005). 
Conformational Changes in the α-Subunit Coupled to Binding of the β2-Subunit of 
Tryptophan Synthase from Escherichia coli:  Crystal Structure of the Tryptophan 
Synthase α-Subunit Alone,. Biochemistry 44, 1184–1192. 
Nishio, K., Ogasahara, K., Morimoto, Y., Tsukihara, T., Lee, S.J., and Yutani, K. (2010). 
Large conformational changes in the Escherichia coli tryptophan synthase β2 subunit 
upon pyridoxal 5′-phosphate binding. FEBS Journal 277, 2157–2170. 
Nowell, H., Attfield, J.P., and Cole, J.C. (2002). 195802: Experimental Crystal Structure 
Determination. The Cambridge Crystallographic Data Centre. 
Okudoh, V.I., and Wallis, F.M. (2007). Antimicrobial activity of rare actinomycetes isolated 
from natural habitats in KwaZulu-Natal, South Africa. South African Journal of 
Science 103, 216–222. 
Okudoh, V.I., and Wallis, F.M. (2012). Enhanced Recovery and Identification of a 
Tryptamine-Related Antibiotic Produced by Intrasporangium N8 from KwaZulu-
Natal, South Africa. Tropical Journal of Pharmaceutical Research 11, 729–737. 
O’Neill, J. (2016). Tackling Drug-Resistant Infections Globally: Final Reports and 
Recommendations (Review on Antimicrobial Resistance). 
R Core Team (2016). R: A Language and Environment for Statistical Computing (Vienna, 
Austria: R Foundation for Statistical Computing). 
Ren, D., Bedzyk, L.A., Ye, R.W., Thomas, S.M., and Wood, T.K. (2004). Stationary-phase 
quorum-sensing signals affect autoinducer-2 and gene expression in Escherichia coli. 
Appl. Environ. Microbiol. 70, 2038–2043. 
Sarker, K.D., and Hardman, J.K. (1995). Affinities of phosphorylated substrates for the E. 
coli tryptophan synthase alpha-subunit: roles of Ser-235 and helix-8’ dipole. Proteins 
21, 130–139. 
 
	
49 
Schneider, T.R., Gerhardt, E., Lee, M., Liang, P.-H., Anderson, K.S., and Schlichting, I. 
(1998). Loop Closure and Intersubunit Communication in Tryptophan Synthase,. 
Biochemistry 37, 5394–5406. 
Silver, L.L. (2007). Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 
6, 41–55. 
Spellberg, B., and Gilbert, D.N. (2014). The Future of Antibiotics and Resistance: A Tribute 
to a Career of Leadership by John Bartlett. Clin Infect Dis 59, S71–S75. 
Sullivan, J.P., McDonnell, L., Hardiman, O.M., Farrell, M.A., Phillips, J.P., and Tipton, K.F. 
(1986). The oxidation of tryptamine by the two forms of monoamine oxidase in 
human tissues. Biochemical Pharmacology 35, 3255–3260. 
Van Boeckel, T.P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B.T., Levin, S.A., and 
Laxminarayan, R. (2014). Global antibiotic consumption 2000 to 2010: an analysis of 
national pharmaceutical sales data. The Lancet Infectious Diseases 14, 742–750. 
Ventola, C.L. (2015). The Antibiotic Resistance Crisis. P T 40, 277–283. 
Viswanathan, V.K. (2014). Off-label abuse of antibiotics by bacteria. Gut Microbes 5, 3–4. 
Wang, D., Ding, X., and Rather, P.N. (2001). Indole can act as an extracellular signal in 
Escherichia coli. J. Bacteriol. 183, 4210–4216. 
White, R.J. (2012). The Early History of Antibiotic Discovery: Empiricism Ruled. 3–31. 
Wickham, H. (2009). ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag New 
York). 
Winzer, K., Hardie, K.R., and Williams, P. (2002). Bacterial cell-to-cell communication: 
sorry, can’t talk now - gone to lunch! Curr. Opin. Microbiol. 5, 216–222. 
Wright, G.D. (2012). The Origins of Antibiotic Resistance. 13–30. 
Yu, P.H. (1985). Some Aspects of the Oxidative Deamination of Tryptamine by MAO-A and 
MAO-B in Different Tissues. In Neuropsychopharmacology of the Trace Amines, 
A.A. Boulton, L. Maitre, P.R. Bieck, and P. Riederer, eds. (Humana Press), pp. 301–
308. 
(2017). ChemDraw Professional (PerkinElmer Informatics). 
The PyMOL Molecular Graphics System (Schrödinger, LLC). 
 
 
 
 
 
 
	
50 
Appendices  
Provisional Patent Application Receipt  
	
 
	
51 
	
 
 
	
52 
 
 
 
	
53 
 
 
 
	
54 
 
